Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sarepta Therapeutics to post earnings of $0.4861 per share and revenue of $381.9780 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. During the same quarter last year, the business posted ($3.42) EPS. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts expect Sarepta Therapeutics to post $4 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Sarepta Therapeutics Price Performance
NASDAQ:SRPT opened at $15.43 on Wednesday. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -16.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.21. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The company’s 50-day moving average is $17.09 and its two-hundred day moving average is $18.83. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $25.32.
Wall Street Analyst Weigh In
Read Our Latest Research Report on Sarepta Therapeutics
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of SRPT. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter worth approximately $25,000. Kestra Advisory Services LLC purchased a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $25,000. Ancora Advisors LLC increased its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the last quarter. Allworth Financial LP increased its position in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,256 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.
Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.
Read More
- Five stocks we like better than Sarepta Therapeutics
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
